Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
about
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerOptimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptorPharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UseHistopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumorsEpidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateA phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901RET fusion gene: translation to personalized lung cancer therapyEpidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet cheProspective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-AnalysisEGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapyA randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer.Targeted Therapies for Lung Cancer.Patient-Reported Physical Function Measures in Cancer Clinical Trials.Postoperative follow-up strategy based on recurrence dynamics for non-small-cell lung cancer.Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.Assessment of sleep disturbance in lung cancer patients: relationship between sleep disturbance and pain, fatigue, quality of life, and psychological distress.Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study.Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).Gefitinib for advanced non-small cell lung cancer.Non-small-cell lung cancer.Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience.ASP8273 tolerability and antitumor activity in TKI-naive Japanese patients with EGFR mutation-positive non-small cell lung cancer.Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations.
P2860
Q26471909-20F6A2C0-95C7-4A09-8B0F-4EEEB753BA6BQ26859993-43DF2E37-4DBA-47B3-9CF5-60A5E7880B3BQ28068930-1CBA1E1D-FCAB-4E38-B534-ACEF2617031CQ28077504-A39998F5-C8B0-490B-A04C-BD2145BB9665Q28284519-2D6D6874-EB62-4DA4-9B7C-ABDA5E3DC5FAQ30356434-04A38643-2652-488A-9069-00DF89DAC8B4Q33406103-BB91F719-21AB-440A-8B12-A079DFFF286FQ33711282-9A93F6E3-9AF5-40ED-BD28-B431357F5121Q34031229-ADA67B17-A58E-405C-97CC-1E58A3DF3E32Q34041768-6D4D25D7-A827-4420-ABF3-83529A18401AQ35151094-902A3DAA-86FF-43EE-A077-25D5DEA7F257Q35975657-ADF58C71-E10F-4BD0-8465-DE91771A97A5Q36118278-B00CB447-A9E6-4ABD-817B-9B1C6612004FQ36224645-39AB5861-5172-45B4-A9B8-ECDA3A7EB75AQ36334253-AA40CAFE-0EBE-480E-915B-5FC4CDF8726CQ36929734-0D5B50E4-7985-427C-9E13-6056AEE9305DQ37566619-1411A947-909A-413B-8071-C099600540C4Q37716649-0E266255-0C54-4A08-97B6-4C6370E9ABE2Q38120309-B8E7CE16-5A2B-4124-9A68-A7846953A8E5Q38481104-C226C257-626F-4783-AE61-A5942737BB15Q38930362-5191FDDA-2E74-4EEF-A635-644C3C3B9535Q39270037-C8AFA0B7-D64E-422E-92A7-6F33F3CC7249Q40961397-6E134FB7-219D-4D76-BC3A-A01F116A54E5Q41452420-5AC33DFD-FCC2-435C-9D9B-0FE179955B56Q41569372-97FD9E79-4BC3-4310-928D-46A5B5AE85E2Q43639934-75A38628-127C-43BF-B0A6-9841F3966F3FQ44701539-A4C7DAC4-77A0-4358-82A0-2FDB7173F1A2Q46691777-626ACBF0-A566-4383-A672-0F2C044B24A2Q48085865-137C2621-F0C3-49D2-A3EE-BAA3E8CE0B21Q48365834-72044973-54A3-4DFB-ACF2-3BBE9A10C2BDQ49605450-DCCE3D5C-F78D-42D3-886E-E69F1B1EF907Q50041281-F73BC296-DD25-4B21-B65E-4DB816AF3BEDQ51021428-037806E4-57DC-4B8E-A1D5-DBC58C0BB070Q51748170-9C110492-BA5E-4AF2-B79E-7F81A5CA3447Q54977912-9C0E0C18-1BF1-4ACB-BB33-B96766B85916Q54982227-EDB224BD-0357-45AF-9D8B-0610118F615E
P2860
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Quality of life with gefitinib ...... t Japan Study Group 002 Trial.
@ast
Quality of life with gefitinib ...... t Japan Study Group 002 Trial.
@en
type
label
Quality of life with gefitinib ...... t Japan Study Group 002 Trial.
@ast
Quality of life with gefitinib ...... t Japan Study Group 002 Trial.
@en
prefLabel
Quality of life with gefitinib ...... t Japan Study Group 002 Trial.
@ast
Quality of life with gefitinib ...... t Japan Study Group 002 Trial.
@en
P2093
P2860
P1433
P1476
Quality of life with gefitinib ...... t Japan Study Group 002 Trial.
@en
P2093
Akihiko Gemma
Akira Inoue
Hirohisa Yoshizawa
Hiroshi Isobe
Ichiro Kinoshita
Koichi Hagiwara
Kunihiko Kobayashi
Makoto Maemondo
Masao Harada
Satoshi Morita
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0426
P577
2012-05-11T00:00:00Z